On March 10, 2022, Colin McCracken, the Chief Commercial Officer of Fluidigm Corporation notified the Company of his intention to resign, effective as of June 12, 2022, after assisting with the Company's transition plan with respect to his role and responsibilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.475 USD | -3.32% | -2.56% | +11.99% |
05-20 | Standard BioTools Receives Shareholder Proposal from Madryn Asset Management | CI |
05-08 | Tranche Update on Standard BioTools Inc.'s Equity Buyback Plan announced on March 1, 2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.99% | 916M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- LAB Stock
- News Standard BioTools Inc.
- Fluidigm Corporation Announces Resignation of Colin McCracken as Chief Commercial Officer, Effective June 12, 2022